#Global Trends – Page 5 – HEALTHCARE INSIGHTS

Key Development Eli Lilly has released detailed Phase III TRIUMPH-2 results for retatrutide, its once-weekly GIP/GLP-1/glucagon triple receptor agonist, in... Read more

Tag: #Global Trends

GE HEALTHCARE BUYS SOFIE FOR $945 MILLION: IN RADIOPHARMA, THE “LAST MILE” IS BECOMING A COMPETITIVE MOAT

ROCHE PUTS UP TO $1.27 BILLION BEHIND AL050: THE PARKINSON’S RACE IS MOVING FROM REPLACING DOPAMINE TO REPAIRING DISEASE BIOLOGY

VAX-31 CLEARS PHASE 3 OPUS-1: THE PNEUMOCOCCAL VACCINE RACE IS SHIFTING FROM “MORE SEROTYPES” TO “BROADER COVERAGE WITHOUT IMMUNE TRADE-OFFS”

2026 MEDICINE NOBEL HONORS OPTOGENETICS: ITS BIGGEST VALUE MAY NOT BE “TREATING THE BRAIN WITH LIGHT” — BUT SHOWING DRUGMAKERS WHICH CIRCUITS ACTUALLY MATTER

PFIZER’S IMMUNOLOGY COUNTEROFFENSIVE: FROM SYSTEMIC ORAL VITILIGO THERAPY TO TRISPECIFIC BIOLOGICS REDEFINING THE STANDARD OF CARE

SANOFI–REGENERON EXPAND ALLIANCE TO AS MUCH AS $8 BILLION: FROM ONE DUPIXENT BLOCKBUSTER TO A NEXT-GENERATION TYPE 2 INFLAMMATION FRANCHISE

PATIENTS SWITCHING FROM INJECTIONS TO THE WEGOVY PILL LOST ANOTHER 4.1%: “ROUTE FLEXIBILITY” COULD BECOME A NEW GLP-1 COMPETITIVE ADVANTAGE

OZEMPIC SHOWS 6% LOWER ASSOCIATED MACE RISK THAN SWITCHING TO MOUNJARO: THE INCRETIN WAR IS MOVING FROM WEIGHT LOSS TO HARD OUTCOMES

RETATRUTIDE DELIVERS NEARLY 21% WEIGHT LOSS IN DIABETES: LILLY IS PUSHING THE GLP-1 RACE FROM “WEIGHT LOSS” TOWARD FULL-SPECTRUM METABOLIC CONTROL

Facebook

Map

Online Members